Seegene Develops New Normalization Software Technology for Molecular Diagnosis

SEOUL, South Korea, Feb. 14, 2017 /PRNewswire/ -- Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies today announced that it has developed a new software technology that can normalize test results of real-time PCR molecular diagnosis systems. This new innovative technology calibrates test results by correcting signal variations from a PCR instrument and can be applied universally to any real-time PCR instruments.

Typically, a variation in signals exists between instruments of the same models or wells within the same model instrument. While manufacturers of instruments strive to address this issue by calibrating hardware, it has remained an unsolved problem, resulting in inconsistent performance in instruments. Seegene has finally found a solution to this problem. Seegene's new software technology successfully overcomes variations in real-time PCR instrumentation, that is, variations from instrument-to-instrument, well-to-well and sample-to-sample. With this new software, test results are automatically normalized, dramatically reducing the possibility of analysis errors and allowing for the reliability of simultaneous multiple diagnostics.

This new technology conducts normalization of instruments to provide consistent results not only within the same model instruments but also among the different model instruments. It promises to become a crucial technology to help expand Seegene's upcoming "one platform MDx solution" to various types of instruments.

Dr. Jong-Yoon Chun, Founder and CEO of Seegene said, "This newly-developed technology provides normalized analysis results by using software which calibrates signal variations. This means as long as the same amplification technology is used, instruments would provide the same analysis results anywhere. It will be the core technology to make possible the expansion of the one platform molecular diagnosis solution that Seegene is pushing forward. Furthermore, this technology could be a fundamental technology to lead the standardization of worldwide molecular diagnosis systems."

Recently, Seegene has announced that its new product portfolio will present 95 new products through its proprietary automated assay development system. As the first step towards the one platform MDx solution, Seegene is developing and preparing more than 10 new products with CE-IVD certification within this year.

About Seegene

Seegene is the world's leading developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx). Seegene's core enabling technologies - DPO™, TOCE™, and MuDT™ - are the foundation for M-MoDx tests that can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility. Seegene's products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene's mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies. For more information, please visit www.seegene.com.

Contact Information

Yoon Chung ([email protected], Tel: 82-2-2240-4082)
Alex Baek ([email protected], Tel: 82-2-2240-4025)

SOURCE Seegene

Related Links

http://www.seegene.com